This Biosimilars Continuing Education series contains seven parts:

Each course within this series is individually accredited. Please their specific catalog listings and overview pages within ScarletCanvas for details.

Biosimilars 101: Introduction to Biologics and Biosimilars

This first course in the Biosimilars Continuing Education Series entitled "Introduction to Biologics and Biosimilars" covers foundational content in Biologics and Biosimilars.

Biosimilars 102: Introduction to Biologics and Biosimilars

This second course in the Biosimilars Continuing Education Series entitled "Biosimilars - Substitution and Interchangeability" will examine U.S. biosimilar substitution policy and practices and will compare these with those of other countries. Physician and patient concerns with these practices will also be discussed.

Biosimilars 103: Biologic and Biosimilar Pharmacovigilance

This third course in the Biosimilars Continuing Education Series entitled "Biologic and Biosimilar Pharmacovigilance" will highlight the unique pharmacovigilance challenges that biosimilars pose and examine the various approaches regulators in the U.S. and elsewhere have implemented to address these challenges.

Biosimilars 104: Physician's Perspectives of Biosimilars

This fourth course in the Biosimilars Continuing Education Series entitled "Physician's Perspectives of Biosimilars", gastroenterologist Ralph Mckibbin, MD shares physician perspectives on key issues surrounding biosimilars. These include physician confidence level in biosimilars, thoughts on when and how they are substituted, and who should control treatment decisions.

Biosimilars 105: The Biosimilars Market

In the fifth course in the Biosimilars Continuing Education Series entitled "The Biosimilar Market", Phil Schneider will discuss the benefits--and challenges--of increasing biosimilar uptake; compare strategies used by different countries to overcome these challenges; and learn which have successfully led to robust, sustainable markets. Recent trends and upcoming developments in the U.S. biosimilar market will be highlighted.

Biosimilars 106: Patient Advocacy Perspectives

The sixth course in the Biosimilars Continuing Education Series entitled "Biosimilars - Patient Advocacy Perspectives" Andrew Spiegel, Esq, examine different perspectives from the patient community regarding biosimilars and how they are made available to patients. The presenter will share his perspective as the head of two international patient organizations, as well as sharing the perspectives of several other patient advocacy experts from the U.S., Europe, Canada, and Australia.

Biosimilars 107: PBMs and Payer Policies

In the seventh and final course in the Biosimilars Continuing Education Series entitled "Biosimilars - PBMs and Payer Policies", Madelaine Feldman, MD, FACR explains unique features of the U.S. drug distribution system, with an emphasis on payer and pharmaceutical benefit manager (PBM) practices regarding biologic medicines and biosimilars.